Abbott and Novo Nordisk Partner to Introduce New Diabetes Drug Extensior in India

Entertainment National Sports Markets Business & Economy Lifestyle World Astrology & Religion Technology Education & Jobs Auto Politics Viral Opinions

Loading more articles...

Abbott, Novo Nordisk Partner to Launch New Diabetes Medication in India

Representational image (Image: News18)

N

News18•27-02-2026, 16:45

Abbott, Novo Nordisk Partner to Launch New Diabetes Medication in India

•Abbott and Novo Nordisk India have partnered to commercialize Extensior, a second brand of Ozempic, for type 2 diabetes treatment.
•The collaboration combines Novo Nordisk’s GLP-1 scientific leadership with Abbott’s distribution network to enhance access in India.
•Extensior contains Semaglutide, which offers significant HbA1c reduction, weight-loss benefits, and reduced cardiovascular and kidney event risks.
•India faces a rapidly growing diabetes burden, projected to reach over 150 million by 2050.
•Abbott will commercialize the brand, which was developed and manufactured by Novo Nordisk.

Read Full Article on News18 in English

✦

More like this

✦

More like this

Mounjaro demand rises in India: Eli Lilly eyes deeper expansion amid GLP-1 boom

Lilly to Boost Mounjaro Access in India Amid Rising Obesity

Representational image (Image: News18)

ICMR's SANVAD 2026 Nurtures Next-Gen Research Leaders, Fostering Innovation & Collaboration

Representational image (Image: News18)

Mauritius PM Arrives in India for Global AI Impact Summit

Representational image (Image: News18)

HyFarm Bets on UP's Warming Climate to Build India's Next French Fry Hub

Representational image (Image: News18)

Fraunhofer Deepens Indo-German AI Partnership at India AI Summit 2026

A Mars orbiter for $74 million, heart surgery for $1,600 and AI without cloud bills — India’s frugal engineering model is reshaping the economics of innovation.

India's 'More with Less' Innovation: From Mangalyaan to Sarvam AI